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Advancements in the treatment of pancreatic cancer 
during the last two decades have been limited mostly 
to the introduction of active, multi-drug chemotherapy 
regimens (such as FOLFIRINOX) or technologies 
aimed at improving the distribution of classic cytotoxic 
drugs (e.g. nab-paclitaxel). The introduction of novel ap-
proaches that have revolutionised systemic treatment in 
several types of solid tumours — targeted therapies and 
immunotherapy — have failed in the field of pancreatic 
cancer. Results of a single positive trial that evaluated 
the combination of gemcitabine and erlotinib, a targeted 
agent aimed at EGFR inhibition, are insignificant from 
clinical point of view because the improvement in overall 
survival was less than minimal. Immunotherapy, includ-
ing both monotherapy and combinations of check-point 
inhibitors, lack the activity seen in other types of cancer. 
This is probably mostly due to the specific microenviron-
ment of pancreatic cancer with abundant extra-cellular 
stroma that create a physical barrier impeding infiltra-
tion of immune cells. As a result, the modern treatment 
of pancreatic cancer still relies on classic cytotoxic drugs, 
mostly multidrug regimens. Without known predictive 
factors, we still cannot predict an optimal chemotherapy 
regimen for a specific patient. The decision between 
FOLFIRINOX and a combination of gemcitabine with 
nab-paclitaxel, the two most commonly used regimens 
in the first-line treatment, depends mostly on the expe-
rience of the physician and on local standards. Some 
retrospective analyses suggest additional benefit from 
platinum agents in patients with known germline mu-
tations in BRCA-family genes. This is based on a defi-
ciency in the homologous recombination repair (HRR) 
mechanism that is present in cells with BRCA mutations, 
leading to the impairment of the double-strain DNA 
break repair. Removal of DNA double-strain breaks, 
created by platinum agents mostly through binding 
purine bases, requires an efficient HRR mechanism. 
Combination of inadequate activity of HRR and the 
presence of platinum compounds may generate a critical 
amount of DNA damage that induces cell death through 
apoptosis or necrosis. An analogous effect in generating 
numerous double-strain DNA breaks in cancer cells 
with non-functional HRR can be achieved with PARP 
inhibitors. Blocking PARP protein, responsible for the 
repair of spontaneous single-strain DNA breaks, allows 
transformation of single-strain breaks into double-strain 
breaks when the cell enters its replication phase. Germi-
nal mutations in BRCA genes are present in 7–10% of 
patients with pancreatic cancer, in many cases without 
familial history of BRCA-related cancers. Transferring 
the results of randomised clinical trials from the general 
population to patients with germinal BRCA mutations, 
we can assume that the optimal first-line chemotherapy 
regimen containing platinum agent is FOLFIRINOX. 
In the classic study published by Conroy in 2011 [1] 
treatment with FOLFIRINOX lasted at least six 
months in the absence of earlier disease progression. 
In clinical practice, achieving a full six months of inten-
sive chemotherapy is difficult and often impossible due 
to cumulative toxicity. One of the possible solutions 
is the concept of induction and maintenance chemo-
therapy, which consists of a short, intensive period of 
FOLFIRINOX (preferably less than six months) with 
prompt de-escalation to a less intensive maintenance 
treatment. This approach was evaluated in the phase 
II PANOPTIMOX trial [2], which compared full 
six-month FOLFIRINOX and shortened four-month 
FOLFIRINOX with LV5FU2 maintenance until 
disease progression. The results show equivalence 
of the de-escalation strategy compared to the classic 
schedule, which is essential for patients poorly tolerat-
ing FOLFIRINOX. Unfortunately, despite improved 
tolerance, the de-escalation strategy failed to improve 
long-term outcomes, including progression-free sur-
vival and overall survival. The search for alternative 
maintenance strategies inspired the idea of using 
PARP inhibitors in pancreatic cancer patients with 
germline mutations in BRCA genes. This is based on 
the molecular mechanisms that provide pre-clinical 
evidence for the idea and the confirmed activity of 
PARP inhibitors as a salvage treatment in this popu-
lation. The achieved results are both a breakthrough, 
because they provide proof that targeted agents offer 
significant activity in the treatment of pancreatic can-
cer, and a disappointment, because no effect on overall 
survival was seen.
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The presented results were published on 2nd July 
2019 in “The New England Journal of Medicine” by 
Golan et al. [3]. The POLO study was a randomised, 
double-blinded, phase 3 trial that compared mainte-
nance olaparib (300 mg orally twice daily) with pla-
cebo in patients with metastatic pancreatic cancer with 
known germline mutation in BRCA1 or BRCA2 genes, 
who received at least four months of platinum-based 
first-line treatment without progression. Recruited 
patients were randomised in a 3:2 ratio to olaparib or 
placebo. No cross-over after progression was allowed. 
The primary endpoint was progression-free survival 
(PFS), with overall survival (OS) as one of the secondary 
endpoints. Among 3315 patients screened for eligibility, 
247 (7.5%) had BRCA mutations, and only 154 patients 
(4.6% of all screened patients) underwent randomisa-
tion. Most of the patients (86% in the olaparib arm and 
81% in the placebo arm) received FOLFIRINOX as the 
first-line treatment. The study met the primary endpoint 
with median PFS of 7.4 months in patients receiving 
olaparib as compared to 3.8 months in patients receiv-
ing placebo (hazard ratio [HR] for progression or death 
0.53; 95% confidence interval [CI] 0.35–0.82; p = 0.004). 
The achieved result remained significant in all analysed 
subgroups and was independent of the type of mutation 
(BRCA1 vs. BRCA2). Available results in term of OS 
are immature (46% of events), but an interim analysis 
showed no statistically significant difference between 
both arms (with median OS 18.9 months in the olaparib 
arm vs. 18.1 months in the placebo arm; HR 0.91; 95% 
CI 0.56–1.46; p = 0.68). In the placebo arm, 14.5% of 
patients received PARP inhibitor after progression. 
The response rate was 20% among patients receiving 
olaparib and 10% among patients receiving placebo, 
with a median duration of response of, respectively, 
24.9 months and 3.7 months. Adverse events grade 
3 or higher were seen in 40% of patients in the olaparib 
arm and in 23% of patients in the placebo arm, with 
serious adverse events seen in, respectively, 24% and 
15% of patients. The most common adverse events in 
the olaparib group were anaemia and fatigue. Patients 
receiving olaparib required treatment with interruptions 
or dose reductions due to adverse events. The rate of 
patients who discontinued the treatment due to toxicity 
was 5% in the olaparib arm and 2% in the placebo arm. 
No treatment-related deaths were seen in either arm. 
Quality of life analysis showed no significant difference 
between the olaparib and placebo arm.
The results of the POLO study bring important 
changes to a certain sub-population of patients with 
pancreatic cancer. The application of olaparib as 
a maintenance treatment for patients with known BRCA 
mutations nearly doubled the progression-free survival. 
This validates PARP inhibitors as an interesting treat-
ment option, justifying evaluation of BRCA1/BRCA2 in 
all patients with pancreatic cancer as a standard. Ad-
ditionally, results of the POLO study are the first to 
show clinically significant improvement with targeted 
therapies in patients with pancreatic cancer. Unfortu-
nately, several aspects of the study limit its popularity. 
Firstly, the proportion of patients who qualified for 
the treatment was more than limited — only 4.5% of 
all screened patients. Secondly, despite the significant 
improvement in PFS, we currently cannot confirm that 
olaparib improves the most important endpoint in onco-
logy — overall survival. Thirdly, treatment with olaparib 
was associated with a significantly higher rate of at least 
grade 3 adverse events and serious adverse events, albeit 
without a negative effect on the quality of life. Neverthe-
less, the POLO study is one of the most important trials 
dedicated to patients with metastatic pancreatic cancer in 
recent years, proving the potential of targeted therapies 
guided by a proper biomarker. We can expect further tri-
als aimed at expanding the role of PARP inhibitors in the 
treatment of patients with pancreatic cancer, searching 
for biomarkers other than BRCA germline mutations.
When less is more — optimising systemic treatment for elderly and/or frail 
patients with gastroesophageal cancers
One of the most fascinating aspects of the annual 
American Society of Clinical Oncology Congress is the 
fact that some studies presented only as abstracts often 
influence clinical practice without the publication of 
full results. While many presented trials are dedicated 
to narrow and limited subgroups without greater impact 
on daily clinical practice, some results affect wide groups 
of patients and provide evidence to revise daily clinical 
decisions, especially when dedicated to less systematised 
areas of modern oncology. One such challenge, with 
growing significance as the populations of Western 
countries age, is providing care for elderly and/or frail 
cancer patients. Frailty syndrome is defined as a state 
of limited functional reserve, mostly due to a decreased 
capacity of more than one organ system, which impairs 
adaptation to stressogenic situations (from physical 
and psychical perspectives). Despite the fact that frailty 
syndrome and older age often co-exist, even separately 
they are demanding and difficult to assess because some 
elderly patients have sufficient functional reserve and 
some younger patients are extremely vulnerable due to 
frailty syndrome. As both elderly and frail patients are 
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underrepresented in clinical trials, it is important to 
notice results of trials dedicated solely to this population.
One such study, the phase 3 GO2 trial, was given as 
an oral presentation and abstract at the 2019 Congress 
of American Society of Clinical Oncology by Hall et al. 
[4]. It was a randomised, phase 3 trial that compared 
different variants of doses of CAPOX in patients with 
gastroesophageal cancer, who were ineligible to the 
EOX regimen due to age and/or frailty syndrome. 
Comparison included three different variants of doses 
of CAPOX: level A — with oxaliplatin 130 mg/m2 on 
day 1 and capecitabine 625 mg/m2 on days 1–21 of every 
21-day cycle; level B — with 80% of doses from level A; 
and level C — with 60% of doses from level A. The 
primary endpoint was a comparison of PFS, with OS 
as one of secondary endpoints. Additionally, the trial 
included evaluation of composite endpoint (called Over-
all Treatment Utility; OTU), which included treatment 
benefit evaluated by a physician, tolerability of treat-
ment, quality of life, and assessment of treatment by the 
patient. The trial included 514 patients, randomised in 
a 1:1:1 ratio to all three treatment arms. Median age was 
76 years in arm A and arm B and 77 years in arm C. In 
each arm about 1/3 of patients had performance status 
(ECOG) 2 or worse, and nearly 80% of patients in each 
arm had frailty syndrome. Median PFS was 4.9 months 
in arm A, 4.1 months in arm B and 4.3 months in arm C, 
which met a prespecified non-inferiority margin for 
comparison of arm B to arm A (HR 1.09; 95% CI 
0.89–1.32) and for comparison of arm C to arm A (HR 
1.10; 95% CI 0.90–1.33). Median OS was 7.5 months in 
arm A, 6.7 months in arm B, and 7.6 months in arm C. In 
arm C, lower rate of non-haematological adverse events 
grade 3 or higher was noted (37% in arm C compared 
to 56% in arm A) as well as better results in terms of 
combined endpoint OTU. No subgroup benefited from 
higher doses of chemotherapy.
Results of the GO2 study provide valuable insights 
into clinical management of elderly and/or frail patients 
with gastroesophageal cancers. In this group, lower 
doses of chemotherapy were associated with a reduced 
rate of adverse events and maintained activity with PFS 
and OS comparable to standard dosing. Additionally, 
probably due to the lower rate of non-haematological 
adverse events, the lowest doses of chemotherapy 
achieved the best results in a combined endpoint that 
evaluated, among others, quality of life. Implementation 
of these results into daily practice may be challenging, 
especially in health care systems with limited financing, 
such as in Poland, due to difficulties with evaluation of 
frailty syndrome. Proper evaluation of frail patients, 
especially when frailty coexists with older age and 
other comorbidities, requires competences not com-
mon among oncologists and additional time, a resource 
that is scarce for most practicing oncologists in Poland. 
Nevertheless, even including the aforementioned diffi-
culties, the improvement of quality of life obtained with 
decreased intensity of chemotherapy highly valuable and 
is extremely important in more vulnerable populations, 
including elderly and frail patients.
Molecular subgroups of low-grade gliomas and effectiveness of PCV 
chemotherapy — a new predictive factor?
Treatment of primary central nervous system tu-
mours in one of the most demanding fields in oncology. 
Proper diagnostics, surgical treatment, radiotherapy, 
and possible systemic treatment not only significantly 
impacts overall survival, but also defines quality of life. 
This includes glioblastoma multiforme, a disease chara-
cterised by uniquely unfavourable prognosis, which 
usually requires multimodality treatment, as well as 
low-grade gliomas in which maintenance of functional 
capabilities and quality of life is nearly as important as 
improvement in overall survival. From this perspective, 
personalisation of treatment and adjustment of intensity 
according to treatment aims is more than crucial. For 
low-grade (G2) gliomas with unfavourable prognostic 
factors — age over 40 years and age under 40 years with 
subtotal tumour resection, since 2016 and publication 
of NRG Oncology/RTOG 9802 trial results, standard 
postoperative treatment consists of radiotherapy and 
subsequent 48-week PCV (procarbazine, lomustine, 
vincristine) chemotherapy [5]. The addition of PCV 
chemotherapy to standard radiotherapy prolonged 
median OS by nearly six years, increasing rate of 
10-year PFS from 21% to 51%. Still, the chemotherapy 
is intensive, long, and associated with high risk of ad-
verse events, mostly haematological. New analysis of 
data from the NRG Oncology/RTOG 9802 study, which 
assessed the newest molecular subgroups of low-grade 
gliomas, gives the opportunity for further optimisation 
of treatment in this group of patients.
The report was presented at an oral session and as 
an abstract on 2019 Congress of American Society of 
Clinical Oncology by Bell et al. [6]. The analysis included 
106 (46%) of 251 patients with grade 2 gliomas, who 
participated in the NRG Oncology/RTOG 9802 study 
and who had tumour sample sufficient to evaluated state 
of IDH1/2 mutation and 1p/19q co-deletion. Mutations 
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in IDH were present in 75% of analysed patients, with 
41% of patients having IDH mutations without 1p/19q 
co-deletion and 35% of patients having both IDH muta-
tion and 1p/19q co-deletion. In a single-factor analysis 
no benefit from PCV chemotherapy was seen in patients 
without IDH mutation, and strong benefit from PCV 
chemotherapy was seen in patients with IDH mutation 
without simultaneous co-deletion (HR for PFS 0.32; 
p = 0.003; HR for OS 0.38; p = 0.013) as well as in pa-
tients with IDH mutation and 1p/19q co-deletion (HR 
for PFS 0.13; p < 0.001; HR for OS 0.21; p = 0.029).
Despite the fact that the analysis is post-hoc and in-
clude only a limited population, it seems that the role of 
IDH as a predictive factor for benefit from postoperative 
PCV chemotherapy in grade 2 gliomas with unfavour-
able risk factor is strong and promising. Evaluation of 
IDH mutation, included currently in the standard WHO 
classification of gliomas, can be a good argument in the 
discussion with patients in favour of chemotherapy. 
Implementation of IDH evaluation provides a very 
rare opportunity for personalised treatment within the 
current standard of care. 
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